PG2 PASSES CLINICAL TRIALS IN CHINA
Cancer Therapy Drug Restores Blood Cells During Chemotherapy
BEIJING - March 19, 2001 - PG2, a plant-derived hematopoiesis enhancer developed by Pharmagenesis, Inc. that restores blood cells after destruction of bone marrow cells induced by chemotherapy, has successfully passed clinical trials in China.
an adjunct to cancer therapy to improve patients’ quality of life, proved
more efficient in stimulating growth of key blood cell lines during
chemotherapy than G-CSF, the positive control product used in the trials.
Chinese New Drug Class II, PG2 was studied in Western-style clinical trials at
the pharmacology unit of Gueng An Men Hospital in Beijing, the most widely
recognized traditional Chinese medicine hospital, and five other hospitals
endorsed by China’s Ministry of Public Health located in China provinces.
clinical trials are regulated by the State Drug Administration (SDA), which is
modeled after the U.S. Food and Drug Administration (FDA). The SDA employs stringent regulations similar to those used
in U.S. drug trials.
trials prove patients who experience blood cell depletion while undergoing
chemotherapy can benefit from PG2,” Nicolas Druz, CEO, Pharmagenesis, said.
“The results substantiate our vision that extracts from plants used
in traditional Chinese medicine are a reliable and cost-efficient source for
the development of new ethical drugs.”
will be sold in China once authorization is granted.
About Pharmagenesis, Inc.
develops anticancer therapies and treatments for cancer therapy-related
bone-marrow suppression and for the management of transplant rejection.
The privately held company focuses on developing ethical pharmaceuticals
from purified extracts of plants that have been employed in traditional Chinese
medicine for more than 4,000 years. Efficacy
is validated by clinical trials conforming to standards of appropriate
government regulatory agencies. Pharmaceuticals
developed and/or licensed by the company are being commercialized initially in
the high-growth markets of China and Taiwan.
corporate headquarters and R & D facility, employing cutting-edge Western
medical research techniques, are located in Palo Alto, Calif.
Pharmagenesis also has operations in Beijing and Taipei.